title: [Mitomicyn C eye drops as alternative treatment for pyogenic granuloma in anophthalmic socket].
abstract: OBJECTIVE
  To evaluate the efficacy of mitomycin C eye drops 0.02% concentration (0.02% MMC) in pyogenic granuloma in anophthalmic socket.
  
  
  METHODS
  Six patients who presented pyogenic granuloma were treated with 0.02% MMC four times a day in fifteen-day cycles with intervals of fifteen days between each cycle. The patients were observed every week.
  
  
  RESULTS
  Among the six studied patients, one presented a complete resolution of the pyogenic granuloma after a ten-day treatment with 0.02% MMC that is, before the end of the first cycle. In two patients, the treatment was successful after two weeks using 0.02% MMC (one complete cycle). In other two patients, the resolution of the lesion occurred after five weeks that is, at the beginning of the second cycle. 0.02% MMC was not successful in only one patient whose lesion persisted after two cycles of the treatment. None of the patients presented complications after the use of 0.02% MMC.
  
  
  CONCLUSIONS
  The topical use of 0.02% MMC proved efficacy in the treatment of anophthalmic socket pyogenic granuloma. A small number of patients took part in this study, therefore another randomized and comparative research is necessary in order to compare the efficacy of 0.02% MMC with other drugs such as corticosteroids and antimetabolites.
authors.affiliation: Serviço de Plástica Ocular, Hospital São Geraldo, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil.
authors.forename: Hérika Danielle de Miranda
authors.initials: HD
authors.lastname: Santos
authors.forename: Thatiana Almeida Pereira
authors.initials: TA
authors.lastname: Fernandes
authors.forename: Cristiano Menezes
authors.initials: CM
authors.lastname: Diniz
authors.forename: Wellington Tadeu
authors.initials: WT
authors.lastname: Montenegro
authors.forename: Ana Rosa Pimentel
authors.initials: AR
authors.lastname: Figueiredo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000853:Anophthalmos / Q000150:complications*; D005260:Female; D005500:Follow-Up Studies; D017789:Granuloma, Pyogenic / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage*; D019384:Nucleic Acid Synthesis Inhibitors / Q000008:administration & dosage*; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D017678:Sex Distribution
chemical_list: D019384:Nucleic Acid Synthesis Inhibitors; D009883:Ophthalmic Solutions; D016685:Mitomycin